The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2- VASc scores ...

Current evidence suggests that percutaneous occlusion of the Left Atrial Appendage (LAA) reduces the risk of thromboembolic complications associated with non-valvular atrial fibrillation. 1 The Amplatzer™ Amulet™ LAA Occluder is designed for complete occlusion of the LAA, thereby reducing the risk for ischemic stroke caused by atrial ...

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS 2 or CHA 2 DS 2-VASc scores ...

Left atrial appendage occlusion is a minimally invasive catheter-based therapy to close the left atrial appendage. The Amplatzer Amulet LAA Occluder provides complete closure, immediately eliminating the need for OACs.

Apatient with the Amplatzer™ Amulet™device can be safely scanned in an MR system under the following conditions: - Staticmagnetic fields of 1.5 Tesla (1.5T) and 3.0 Tesla (3.0T) -...

2021年8月16日 · Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke - Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn't needed following implantation

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS 2 or CHA 2 DS 2-VASc scores ...

2024年11月18日 · The 5-year outcomes from the largest randomized LAAO clinical trial demonstrated the long-term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices. The dual-seal Amulet occluder reduces atrial fibrillation–related thromboembolic events while eliminating the need for long-term OAC.

This document provides a consensus approach developed by experts on the steps of left atrial appendage occlusion technique and best practices for implantation of the AMPLATZER Amulet device, along with tips to minimize complications.

To evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) with the Amplatzer™ Amulet™ occluder. Patients with atrial fibrillation eligible for LAAO were recruited to a prospective global study.